Metraipolis › archive › dc_f7438aaae49e
Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42514194
- DOI
- 10.3390/life16071124
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T11:04:52.006Z
- SHA-256 of the archived text
ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92- Stable URL of this page
https://metraipolis.com/documento/dc_f7438aaae49e
How to cite
Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194 — Europe PMC (en), https://europepmc.org/article/MED/42514194 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f7438aaae49e (Metraipolis archive dc_f7438aaae49e, sha256 ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92)
BibTeX
@misc{dcf7438aaae49e,
title = {Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42514194},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f7438aaae49e; sha256 ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42514194. Agents can read the archived copy with the MCP tool read_document.